



# CURVEBEAM AI AGM

November 2023



---

# DISCLAIMER

## Introduction

This presentation has been prepared by CurveBeam AI Limited (ACN 140 706 618) (**CurveBeam** or the **Company**) and contains summary information about CurveBeam and the business conducted by it as at 22 November 2023. The information in this presentation is for informational purposes only, does not purport to be complete and is not a prospectus, product disclosure statement or other disclosure document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (**Act**) or other offer document under Australian law or the law of any other jurisdiction.

The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This document may not be distributed or released to any person in the United States.

As further detailed below, none of CurveBeam, nor its advisers (**Advisers**) nor their respective affiliates, related bodies corporate (as defined in the Act) or security holders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) guarantees or make any representation or warranty to, or takes responsibility for, the accuracy, reliability or completeness of the information contained in this presentation, to the recipient of this document (you or the Recipient), and nothing contained in this document is, or may be relied upon as, a promise or representation, whether as to the past or future. To the maximum extent permitted by law, each Limited Party disclaims any liability for any loss arising from the use of information including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

## Not an offer or financial product advice

The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect the purchase or sale of any securities in CurveBeam nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Recipients of the presentation must undertake their own independent investigations, consideration and evaluation. By accepting this presentation, a Recipient agrees that if it proceeds further with its investigations, consideration or evaluation of investing in CurveBeam it will not in any way rely upon this document. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision.

CurveBeam recommends that potential investors consult their professional advisors as an investment in CurveBeam is subject to investment and other known and unknown risks, some of which are beyond the control of CurveBeam or its directors and therefore any investment is considered to be speculative in nature.

## Forward looking statements

The information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of CurveBeam's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "should", "could", "may" and other similar expressions

are intended to identify future earnings, financial position and performance of CurveBeam. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by CurveBeam about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding CurveBeam's present and future business strategies and the political, regulatory and economic environment in which CurveBeam will operate in the future and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance.

The actual results or performance of CurveBeam may be materially different from the results or performance expressed or implied by such forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur). Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.

## Financial information

All numbers in this presentation are stated in Australian dollars (**A\$**) unless stated otherwise.

## FY23 CURVEBEAM AI HIGHLIGHTS

- StraxCorp and CurveBeam **merger completed** in Q1 FY23
- **Pre-IPO round closed** Q3 FY23 – raised \$25m
- The pre-IPO round showed a **number of new institutional investors** join our register.
- Listed on ASX - **raised A\$25m** in August 2023 – (ASX: CVB)
- FY23 proforma revenue **A\$11.48m, circa 55% growth on FY22**
- Foot & Ankle (F&A) division of Stryker continues to build a **strong prospects pipeline**
- Primary company focus for FY24 is to place HiRise™ as quickly as possible – especially in the US market and to **launch BMD SaaS model** once FDA clearance is achieved




## STRYKER FOOT & ANKLE UPDATE



### STRYKER CORPORATION - FOOT & ANKLE DIVISION

- Training for Stryker F&A occurred in late January 2023
- Stryker approved CurveBeam AI Limited as an approved supplier in May and made available financing options in June/July 2023
- AOFAS Conference – 20<sup>th</sup> to 23<sup>rd</sup> September 2023
- Met with numerous prospects to see firsthand the opportunity HiRise™ has and where a lot of prospects are in the sales cycle
- The challenges to closing accounts include 1) reimbursement support, & 2) access to HiRise™ for knee & hip Total Joint Replacement (TJR) data sets for robotic systems

## ENHANCED HIRISE™ PROJECT



### STRYKER CORPORATION - FOOT & ANKLE DIVISION

- CurveBeam AI is developing enhancements to the HiRise™ platform, including a stronger X-Ray source for larger patients
- This will enable higher resolution scans of the hip & knee required for surgical systems & patient specific instrumentation (PSI)
- The enhanced image should improve image details and diagnostics
- Targeting scans to be available to vendors in Q2/Q3 FY24 for validation of instrument/robot specific data sets
- Targeting validation of datasets for robotics systems in Q4 FY24
- The Company is targeting commercial launch of the enhanced HiRise™ platform around Q1 FY25
- The HiRise™ system upgrade is also critical for offering the AI SaaS based CT BMD module on the HiRise™



## BMD HIRISE™ MODULE PROGRESS



- Target of the BMD module is to build a recurring high margin revenue
- The new enhanced HiRise™ is needed to deploy a BMD product (post FDA)
- Company has identified & started discussions with several US sites for enrolling/collecting patients data for FDA submission
- Planning a submission to the FDA [510(k)] for HiRise™ BMD in June/July 2024, FDA clearance targeted for late FY25
- FDA granted the **OssView (SFS)** a Breakthrough Device designation in 2022
  - Company is targeting FDA clearance for OssView (wrist) on the InReach HRpQCT as a step to conducting an integrated network trial to build reimbursement for a US capitated market & target US Medicare reimbursement
  - Following discussions with the FDA, the Company has decided to re-file a broader 510(k) clearance for OssView (wrist) for the InReach under the Breakthrough Designation pathway
  - The new file clearance is now targeted for end of CY24 (vs end of FY2024 for original filing) - the targeted network trial timeline remains unchanged

## IN CLOSING

- **Deploying IPO capital** to support HiRise™ placements for the rest of FY24
- The **company focus** remains
  1. Driving growth in HiRise™ placements – especially in the US
  2. Enhanced HiRise™ platform, especially for PSI & BMD functionality
  3. Target launch for BMD SaaS business by the end of FY25
- FY24 orders – **Company remains optimistic** regarding the outlook for Stryker driven placements and sales. Timing of when sales are closed & booked remains outside the Company's control
- Advancing enhanced HiRise™ platform for **robotic system datasets** to target
  - Accelerating orders – Robotic Hip & Knee users in a group practice need validation from Stryker that HiRise™ can be used for other robotic datasets
  - Improve diagnostic information for conditions identification around the hip & Knee
- US FDA filing **bone mineral density (BMD) SaaS module** – FDA clearance remains on late FY25 target

